REF_DATE,GEO,DGUID,Measure,Sex at birth,Age group,Characteristics,UOM,UOM_ID,SCALAR_FACTOR,SCALAR_ID,VECTOR,COORDINATE,VALUE,STATUS,SYMBOL,TERMINATED,DECIMALS
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877124,1.1.1.1.1,3.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877125,1.1.1.1.2,2.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877126,1.1.1.1.3,4.2,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877127,1.1.1.2.1,3.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877128,1.1.1.2.2,2.2,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877129,1.1.1.2.3,4.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877130,1.1.1.3.1,4.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877131,1.1.1.3.2,3.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877132,1.1.1.3.3,5.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877133,1.1.1.4.1,2.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877134,1.1.1.4.2,1.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877135,1.1.1.4.3,2.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877136,1.1.2.1.1,3.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877137,1.1.2.1.2,2.2,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877138,1.1.2.1.3,4.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877139,1.1.2.2.1,3.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877140,1.1.2.2.2,2.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877141,1.1.2.2.3,6.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877142,1.1.2.3.1,3.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877143,1.1.2.3.2,2.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877144,1.1.2.3.3,5.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877145,1.1.2.4.1,2.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877146,1.1.2.4.2,1.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877147,1.1.2.4.3,3.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877148,1.1.3.1.1,3.9,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877149,1.1.3.1.2,2.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877150,1.1.3.1.3,4.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877151,1.1.3.2.1,3.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877152,1.1.3.2.2,1.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877153,1.1.3.2.3,4.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877154,1.1.3.3.1,5.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877155,1.1.3.3.2,3.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877156,1.1.3.3.3,6.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877157,1.1.3.4.1,2.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877158,1.1.3.4.2,0.9,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877159,1.1.3.4.3,3.2,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877160,1.2.1.1.1,2.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877161,1.2.1.1.2,1.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877162,1.2.1.1.3,3.2,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877163,1.2.1.2.1,3.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877164,1.2.1.2.2,2.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877165,1.2.1.2.3,4.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877166,1.2.1.3.1,2.9,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877167,1.2.1.3.2,1.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877168,1.2.1.3.3,3.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877169,1.2.1.4.1,1.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877170,1.2.1.4.2,0.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877171,1.2.1.4.3,1.9,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877172,1.2.2.1.1,2.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877173,1.2.2.1.2,1.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877174,1.2.2.1.3,3.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877175,1.2.2.2.1,3.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877176,1.2.2.2.2,2.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877177,1.2.2.2.3,6.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877178,1.2.2.3.1,3.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877179,1.2.2.3.2,1.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877180,1.2.2.3.3,4.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877181,1.2.2.4.1,1.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877182,1.2.2.4.2,0.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877183,1.2.2.4.3,2.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877184,1.2.3.1.1,2.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877185,1.2.3.1.2,1.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877186,1.2.3.1.3,3.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877187,1.2.3.2.1,2.9,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877188,1.2.3.2.2,1.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877189,1.2.3.2.3,4.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877190,1.2.3.3.1,2.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877191,1.2.3.3.2,1.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877192,1.2.3.3.3,3.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877193,1.2.3.4.1,1.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877194,1.2.3.4.2,0.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877195,1.2.3.4.3,1.9,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877196,1.3.1.1.1,1.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877197,1.3.1.1.2,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877198,1.3.1.1.3,1.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877199,1.3.1.2.1,,x,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877200,1.3.1.2.2,,x,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877201,1.3.1.2.3,,x,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877202,1.3.1.3.1,1.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877203,1.3.1.3.2,0.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877204,1.3.1.3.3,2.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877205,1.3.1.4.1,0.7,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877206,1.3.1.4.2,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877207,1.3.1.4.3,1.2,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877208,1.3.2.1.1,0.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877209,1.3.2.1.2,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877210,1.3.2.1.3,0.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877211,1.3.2.2.1,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877212,1.3.2.2.2,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877213,1.3.2.2.3,0.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877214,1.3.2.3.1,0.6,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877215,1.3.2.3.2,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877216,1.3.2.3.3,1.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877217,1.3.2.4.1,0.4,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877218,1.3.2.4.2,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877219,1.3.2.4.3,0.8,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877220,1.3.3.1.1,1.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877221,1.3.3.1.2,0.5,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877222,1.3.3.1.3,2.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877223,1.3.3.2.1,,x,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877224,1.3.3.2.2,,x,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877225,1.3.3.2.3,,x,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877226,1.3.3.3.1,2.3,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877227,1.3.3.3.2,1.2,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877228,1.3.3.3.3,3.1,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877229,1.3.3.4.1,0.9,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877230,1.3.3.4.2,0.0,,,,1
2021,Canada,2016A000011124,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877231,1.3.3.4.3,2.1,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877232,2.1.1.1.1,1.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877233,2.1.1.1.2,0.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877234,2.1.1.1.3,1.8,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877235,2.1.1.2.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877236,2.1.1.2.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877237,2.1.1.2.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877238,2.1.1.3.1,2.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877239,2.1.1.3.2,0.9,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877240,2.1.1.3.3,2.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877241,2.1.1.4.1,0.9,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877242,2.1.1.4.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877243,2.1.1.4.3,1.8,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877244,2.1.2.1.1,1.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877245,2.1.2.1.2,0.6,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877246,2.1.2.1.3,2.6,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877247,2.1.2.2.1,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877248,2.1.2.2.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877249,2.1.2.2.3,1.5,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877250,2.1.2.3.1,2.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877251,2.1.2.3.2,1.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877252,2.1.2.3.3,4.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877253,2.1.2.4.1,1.4,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877254,2.1.2.4.2,0.2,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877255,2.1.2.4.3,3.2,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877256,2.1.3.1.1,1.1,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877257,2.1.3.1.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877258,2.1.3.1.3,1.6,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877259,2.1.3.2.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877260,2.1.3.2.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877261,2.1.3.2.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877262,2.1.3.3.1,1.5,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877263,2.1.3.3.2,0.4,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877264,2.1.3.3.3,2.5,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877265,2.1.3.4.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877266,2.1.3.4.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877267,2.1.3.4.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877268,2.2.1.1.1,0.5,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877269,2.2.1.1.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877270,2.2.1.1.3,0.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877271,2.2.1.2.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877272,2.2.1.2.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877273,2.2.1.2.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877274,2.2.1.3.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877275,2.2.1.3.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877276,2.2.1.3.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877277,2.2.1.4.1,0.8,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877278,2.2.1.4.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877279,2.2.1.4.3,1.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877280,2.2.2.1.1,0.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877281,2.2.2.1.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877282,2.2.2.1.3,1.4,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877283,2.2.2.2.1,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877284,2.2.2.2.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877285,2.2.2.2.3,1.5,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877286,2.2.2.3.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877287,2.2.2.3.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877288,2.2.2.3.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877289,2.2.2.4.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877290,2.2.2.4.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877291,2.2.2.4.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877292,2.2.3.1.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877293,2.2.3.1.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877294,2.2.3.1.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877295,2.2.3.2.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877296,2.2.3.2.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877297,2.2.3.2.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877298,2.2.3.3.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877299,2.2.3.3.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877300,2.2.3.3.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877301,2.2.3.4.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877302,2.2.3.4.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877303,2.2.3.4.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877304,2.3.1.1.1,0.9,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877305,2.3.1.1.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877306,2.3.1.1.3,1.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877307,2.3.1.2.1,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877308,2.3.1.2.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877309,2.3.1.2.3,0.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877310,2.3.1.3.1,1.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877311,2.3.1.3.2,0.6,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877312,2.3.1.3.3,2.4,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877313,2.3.1.4.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877314,2.3.1.4.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877315,2.3.1.4.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877316,2.3.2.1.1,1.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877317,2.3.2.1.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877318,2.3.2.1.3,1.7,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877319,2.3.2.2.1,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877320,2.3.2.2.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877321,2.3.2.2.3,1.5,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877322,2.3.2.3.1,2.1,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877323,2.3.2.3.2,0.9,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877324,2.3.2.3.3,3.5,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877325,2.3.2.4.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877326,2.3.2.4.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877327,2.3.2.4.3,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877328,2.3.3.1.1,0.8,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877329,2.3.3.1.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877330,2.3.3.1.3,1.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877331,2.3.3.2.1,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877332,2.3.3.2.2,0.0,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877333,2.3.3.2.3,1.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877334,2.3.3.3.1,1.4,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877335,2.3.3.3.2,0.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877336,2.3.3.3.3,2.3,,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877337,2.3.3.4.1,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877338,2.3.3.4.2,,x,,,1
2021,Atlantic Region,2016A00011,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877339,2.3.3.4.3,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877340,3.1.1.1.1,4.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877341,3.1.1.1.2,3.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877342,3.1.1.1.3,5.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877343,3.1.1.2.1,5.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877344,3.1.1.2.2,3.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877345,3.1.1.2.3,7.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877346,3.1.1.3.1,5.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877347,3.1.1.3.2,3.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877348,3.1.1.3.3,7.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877349,3.1.1.4.1,2.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877350,3.1.1.4.2,0.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877351,3.1.1.4.3,5.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877352,3.1.2.1.1,3.9,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877353,3.1.2.1.2,2.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877354,3.1.2.1.3,5.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877355,3.1.2.2.1,4.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877356,3.1.2.2.2,2.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877357,3.1.2.2.3,8.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877358,3.1.2.3.1,4.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877359,3.1.2.3.2,2.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877360,3.1.2.3.3,6.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877361,3.1.2.4.1,3.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877362,3.1.2.4.2,1.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877363,3.1.2.4.3,7.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877364,3.1.3.1.1,4.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877365,3.1.3.1.2,3.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877366,3.1.3.1.3,6.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877367,3.1.3.2.1,5.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877368,3.1.3.2.2,3.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877369,3.1.3.2.3,9.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877370,3.1.3.3.1,6.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877371,3.1.3.3.2,3.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877372,3.1.3.3.3,9.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877373,3.1.3.4.1,1.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877374,3.1.3.4.2,0.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877375,3.1.3.4.3,5.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877376,3.2.1.1.1,3.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877377,3.2.1.1.2,2.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877378,3.2.1.1.3,4.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877379,3.2.1.2.1,5.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877380,3.2.1.2.2,3.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877381,3.2.1.2.3,7.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877382,3.2.1.3.1,3.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877383,3.2.1.3.2,1.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877384,3.2.1.3.3,5.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877385,3.2.1.4.1,1.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877386,3.2.1.4.2,0.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877387,3.2.1.4.3,4.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877388,3.2.2.1.1,3.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877389,3.2.2.1.2,2.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877390,3.2.2.1.3,4.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877391,3.2.2.2.1,4.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877392,3.2.2.2.2,2.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877393,3.2.2.2.3,8.3,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877394,3.2.2.3.1,3.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877395,3.2.2.3.2,1.5,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877396,3.2.2.3.3,5.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877397,3.2.2.4.1,2.5,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877398,3.2.2.4.2,0.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877399,3.2.2.4.3,6.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877400,3.2.3.1.1,3.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877401,3.2.3.1.2,1.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877402,3.2.3.1.3,4.5,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877403,3.2.3.2.1,5.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877404,3.2.3.2.2,3.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877405,3.2.3.2.3,9.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877406,3.2.3.3.1,3.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877407,3.2.3.3.2,1.8,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877408,3.2.3.3.3,5.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877409,3.2.3.4.1,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877410,3.2.3.4.2,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877411,3.2.3.4.3,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877412,3.3.1.1.1,1.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877413,3.3.1.1.2,0.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877414,3.3.1.1.3,1.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877415,3.3.1.2.1,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877416,3.3.1.2.2,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877417,3.3.1.2.3,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877418,3.3.1.3.1,1.9,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877419,3.3.1.3.2,0.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877420,3.3.1.3.3,3.1,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877421,3.3.1.4.1,0.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877422,3.3.1.4.2,0.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877423,3.3.1.4.3,2.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877424,3.3.2.1.1,0.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877425,3.3.2.1.2,0.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877426,3.3.2.1.3,1.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877427,3.3.2.2.1,0.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877428,3.3.2.2.2,0.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877429,3.3.2.2.3,1.5,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877430,3.3.2.3.1,1.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877431,3.3.2.3.2,0.0,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877432,3.3.2.3.3,2.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877433,3.3.2.4.1,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877434,3.3.2.4.2,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877435,3.3.2.4.3,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877436,3.3.3.1.1,1.7,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877437,3.3.3.1.2,0.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877438,3.3.3.1.3,2.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877439,3.3.3.2.1,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877440,3.3.3.2.2,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877441,3.3.3.2.3,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877442,3.3.3.3.1,2.6,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877443,3.3.3.3.2,1.2,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877444,3.3.3.3.3,4.4,,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877445,3.3.3.4.1,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877446,3.3.3.4.2,,x,,,1
2021,Quebec,2016A000224,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877447,3.3.3.4.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877448,4.1.1.1.1,3.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877449,4.1.1.1.2,1.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877450,4.1.1.1.3,5.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877451,4.1.1.2.1,2.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877452,4.1.1.2.2,0.9,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877453,4.1.1.2.3,5.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877454,4.1.1.3.1,4.4,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877455,4.1.1.3.2,2.7,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877456,4.1.1.3.3,6.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877457,4.1.1.4.1,1.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877458,4.1.1.4.2,0.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877459,4.1.1.4.3,3.2,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877460,4.1.2.1.1,2.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877461,4.1.2.1.2,1.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877462,4.1.2.1.3,4.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877463,4.1.2.2.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877464,4.1.2.2.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877465,4.1.2.2.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877466,4.1.2.3.1,3.4,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877467,4.1.2.3.2,1.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877468,4.1.2.3.3,6.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877469,4.1.2.4.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877470,4.1.2.4.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877471,4.1.2.4.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877472,4.1.3.1.1,3.8,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877473,4.1.3.1.2,2.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877474,4.1.3.1.3,5.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877475,4.1.3.2.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877476,4.1.3.2.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877477,4.1.3.2.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877478,4.1.3.3.1,5.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877479,4.1.3.3.2,3.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877480,4.1.3.3.3,7.9,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877481,4.1.3.4.1,2.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877482,4.1.3.4.2,0.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877483,4.1.3.4.3,5.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877484,4.2.1.1.1,2.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877485,4.2.1.1.2,1.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877486,4.2.1.1.3,4.4,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877487,4.2.1.2.1,2.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877488,4.2.1.2.2,0.9,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877489,4.2.1.2.3,5.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877490,4.2.1.3.1,3.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877491,4.2.1.3.2,1.8,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877492,4.2.1.3.3,5.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877493,4.2.1.4.1,0.8,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877494,4.2.1.4.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877495,4.2.1.4.3,2.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877496,4.2.2.1.1,2.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877497,4.2.2.1.2,1.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877498,4.2.2.1.3,4.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877499,4.2.2.2.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877500,4.2.2.2.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877501,4.2.2.2.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877502,4.2.2.3.1,3.4,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877503,4.2.2.3.2,1.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877504,4.2.2.3.3,6.5,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877505,4.2.2.4.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877506,4.2.2.4.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877507,4.2.2.4.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877508,4.2.3.1.1,2.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877509,4.2.3.1.2,1.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877510,4.2.3.1.3,3.7,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877511,4.2.3.2.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877512,4.2.3.2.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877513,4.2.3.2.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877514,4.2.3.3.1,3.2,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877515,4.2.3.3.2,1.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877516,4.2.3.3.3,5.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877517,4.2.3.4.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877518,4.2.3.4.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877519,4.2.3.4.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877520,4.3.1.1.1,0.8,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877521,4.3.1.1.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877522,4.3.1.1.3,1.9,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877523,4.3.1.2.1,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877524,4.3.1.2.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877525,4.3.1.2.3,1.4,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877526,4.3.1.3.1,1.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877527,4.3.1.3.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877528,4.3.1.3.3,2.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877529,4.3.1.4.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877530,4.3.1.4.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877531,4.3.1.4.3,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877532,4.3.2.1.1,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877533,4.3.2.1.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877534,4.3.2.1.3,0.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877535,4.3.2.2.1,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877536,4.3.2.2.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877537,4.3.2.2.3,3.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877538,4.3.2.3.1,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877539,4.3.2.3.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877540,4.3.2.3.3,1.1,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877541,4.3.2.4.1,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877542,4.3.2.4.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877543,4.3.2.4.3,1.8,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877544,4.3.3.1.1,1.4,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877545,4.3.3.1.2,0.3,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877546,4.3.3.1.3,2.4,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877547,4.3.3.2.1,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877548,4.3.3.2.2,0.0,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877549,4.3.3.2.3,2.7,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877550,4.3.3.3.1,1.9,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877551,4.3.3.3.2,0.6,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877552,4.3.3.3.3,3.7,,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877553,4.3.3.4.1,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877554,4.3.3.4.2,,x,,,1
2021,Ontario,2016A000235,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877555,4.3.3.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877556,5.1.1.1.1,3.1,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877557,5.1.1.1.2,1.8,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877558,5.1.1.1.3,4.5,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877559,5.1.1.2.1,4.3,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877560,5.1.1.2.2,1.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877561,5.1.1.2.3,9.9,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877562,5.1.1.3.1,3.3,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877563,5.1.1.3.2,1.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877564,5.1.1.3.3,5.8,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877565,5.1.1.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877566,5.1.1.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877567,5.1.1.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877568,5.1.2.1.1,2.5,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877569,5.1.2.1.2,1.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877570,5.1.2.1.3,5.2,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877571,5.1.2.2.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877572,5.1.2.2.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877573,5.1.2.2.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877574,5.1.2.3.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877575,5.1.2.3.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877576,5.1.2.3.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877577,5.1.2.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877578,5.1.2.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877579,5.1.2.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877580,5.1.3.1.1,3.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877581,5.1.3.1.2,2.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877582,5.1.3.1.3,5.7,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877583,5.1.3.2.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877584,5.1.3.2.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877585,5.1.3.2.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877586,5.1.3.3.1,4.3,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877587,5.1.3.3.2,2.2,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877588,5.1.3.3.3,7.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877589,5.1.3.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877590,5.1.3.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877591,5.1.3.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877592,5.2.1.1.1,2.4,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877593,5.2.1.1.2,1.2,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877594,5.2.1.1.3,3.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877595,5.2.1.2.1,4.3,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877596,5.2.1.2.2,1.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877597,5.2.1.2.3,9.9,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877598,5.2.1.3.1,2.4,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877599,5.2.1.3.2,0.8,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877600,5.2.1.3.3,4.9,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877601,5.2.1.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877602,5.2.1.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877603,5.2.1.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877604,5.2.2.1.1,2.4,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877605,5.2.2.1.2,0.9,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877606,5.2.2.1.3,5.1,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877607,5.2.2.2.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877608,5.2.2.2.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877609,5.2.2.2.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877610,5.2.2.3.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877611,5.2.2.3.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877612,5.2.2.3.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877613,5.2.2.4.1,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877614,5.2.2.4.2,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877615,5.2.2.4.3,3.2,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877616,5.2.3.1.1,2.4,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877617,5.2.3.1.2,1.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877618,5.2.3.1.3,4.3,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877619,5.2.3.2.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877620,5.2.3.2.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877621,5.2.3.2.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877622,5.2.3.3.1,2.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877623,5.2.3.3.2,0.9,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877624,5.2.3.3.3,5.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877625,5.2.3.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877626,5.2.3.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877627,5.2.3.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877628,5.3.1.1.1,0.7,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877629,5.3.1.1.2,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877630,5.3.1.1.3,1.5,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877631,5.3.1.2.1,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877632,5.3.1.2.2,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877633,5.3.1.2.3,2.5,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877634,5.3.1.3.1,1.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877635,5.3.1.3.2,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877636,5.3.1.3.3,2.3,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877637,5.3.1.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877638,5.3.1.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877639,5.3.1.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877640,5.3.2.1.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877641,5.3.2.1.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877642,5.3.2.1.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877643,5.3.2.2.1,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877644,5.3.2.2.2,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877645,5.3.2.2.3,5.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877646,5.3.2.3.1,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877647,5.3.2.3.2,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877648,5.3.2.3.3,1.9,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877649,5.3.2.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877650,5.3.2.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877651,5.3.2.4.3,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877652,5.3.3.1.1,1.2,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877653,5.3.3.1.2,0.1,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877654,5.3.3.1.3,2.6,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877655,5.3.3.2.1,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877656,5.3.3.2.2,0.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877657,5.3.3.2.3,4.7,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877658,5.3.3.3.1,1.7,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877659,5.3.3.3.2,0.4,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877660,5.3.3.3.3,4.0,,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877661,5.3.3.4.1,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877662,5.3.3.4.2,,x,,,1
2021,Manitoba,2016A000246,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877663,5.3.3.4.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877664,6.1.1.1.1,4.1,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877665,6.1.1.1.2,2.6,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877666,6.1.1.1.3,5.7,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877667,6.1.1.2.1,5.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877668,6.1.1.2.2,2.2,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877669,6.1.1.2.3,10.4,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877670,6.1.1.3.1,3.1,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877671,6.1.1.3.2,0.9,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877672,6.1.1.3.3,8.2,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877673,6.1.1.4.1,5.1,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877674,6.1.1.4.2,2.3,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877675,6.1.1.4.3,10.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877676,6.1.2.1.1,3.5,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877677,6.1.2.1.2,1.8,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877678,6.1.2.1.3,5.9,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877679,6.1.2.2.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877680,6.1.2.2.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877681,6.1.2.2.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877682,6.1.2.3.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877683,6.1.2.3.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877684,6.1.2.3.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877685,6.1.2.4.1,4.2,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877686,6.1.2.4.2,1.5,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877687,6.1.2.4.3,10.2,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877688,6.1.3.1.1,4.7,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877689,6.1.3.1.2,2.5,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877690,6.1.3.1.3,7.8,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877691,6.1.3.2.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877692,6.1.3.2.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877693,6.1.3.2.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877694,6.1.3.3.1,4.0,E,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877695,6.1.3.3.2,1.1,E,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877696,6.1.3.3.3,12.3,E,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877697,6.1.3.4.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877698,6.1.3.4.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877699,6.1.3.4.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877700,6.2.1.1.1,2.9,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877701,6.2.1.1.2,1.6,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877702,6.2.1.1.3,4.3,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877703,6.2.1.2.1,5.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877704,6.2.1.2.2,2.2,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877705,6.2.1.2.3,10.4,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877706,6.2.1.3.1,1.8,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877707,6.2.1.3.2,0.3,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877708,6.2.1.3.3,5.1,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877709,6.2.1.4.1,2.8,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877710,6.2.1.4.2,1.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877711,6.2.1.4.3,6.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877712,6.2.2.1.1,3.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877713,6.2.2.1.2,1.4,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877714,6.2.2.1.3,5.3,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877715,6.2.2.2.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877716,6.2.2.2.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877717,6.2.2.2.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877718,6.2.2.3.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877719,6.2.2.3.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877720,6.2.2.3.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877721,6.2.2.4.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877722,6.2.2.4.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877723,6.2.2.4.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877724,6.2.3.1.1,2.9,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877725,6.2.3.1.2,1.3,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877726,6.2.3.1.3,5.1,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877727,6.2.3.2.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877728,6.2.3.2.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877729,6.2.3.2.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877730,6.2.3.3.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877731,6.2.3.3.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877732,6.2.3.3.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877733,6.2.3.4.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877734,6.2.3.4.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877735,6.2.3.4.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877736,6.3.1.1.1,1.2,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877737,6.3.1.1.2,0.1,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877738,6.3.1.1.3,2.2,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877739,6.3.1.2.1,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877740,6.3.1.2.2,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877741,6.3.1.2.3,2.4,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877742,6.3.1.3.1,1.3,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877743,6.3.1.3.2,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877744,6.3.1.3.3,4.9,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877745,6.3.1.4.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877746,6.3.1.4.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877747,6.3.1.4.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877748,6.3.2.1.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877749,6.3.2.1.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877750,6.3.2.1.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877751,6.3.2.2.1,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877752,6.3.2.2.2,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877753,6.3.2.2.3,4.8,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877754,6.3.2.3.1,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877755,6.3.2.3.2,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877756,6.3.2.3.3,2.1,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877757,6.3.2.4.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877758,6.3.2.4.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877759,6.3.2.4.3,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877760,6.3.3.1.1,1.8,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877761,6.3.3.1.2,0.4,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877762,6.3.3.1.3,4.5,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877763,6.3.3.2.1,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877764,6.3.3.2.2,0.0,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877765,6.3.3.2.3,4.5,,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877766,6.3.3.3.1,2.4,E,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877767,6.3.3.3.2,0.5,E,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877768,6.3.3.3.3,8.5,E,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877769,6.3.3.4.1,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877770,6.3.3.4.2,,x,,,1
2021,Saskatchewan,2016A000247,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877771,6.3.3.4.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877772,7.1.1.1.1,5.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877773,7.1.1.1.2,4.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877774,7.1.1.1.3,7.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877775,7.1.1.2.1,4.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877776,7.1.1.2.2,1.9,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877777,7.1.1.2.3,8.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877778,7.1.1.3.1,6.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877779,7.1.1.3.2,3.2,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877780,7.1.1.3.3,10.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877781,7.1.1.4.1,6.2,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877782,7.1.1.4.2,3.2,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877783,7.1.1.4.3,11.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877784,7.1.2.1.1,6.2,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877785,7.1.2.1.2,4.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877786,7.1.2.1.3,9.1,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877787,7.1.2.2.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877788,7.1.2.2.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877789,7.1.2.2.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877790,7.1.2.3.1,5.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877791,7.1.2.3.2,2.9,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877792,7.1.2.3.3,10.1,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877793,7.1.2.4.1,7.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877794,7.1.2.4.2,3.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877795,7.1.2.4.3,13.8,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877796,7.1.3.1.1,5.1,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877797,7.1.3.1.2,2.9,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877798,7.1.3.1.3,8.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877799,7.1.3.2.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877800,7.1.3.2.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877801,7.1.3.2.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877802,7.1.3.3.1,6.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877803,7.1.3.3.2,2.8,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877804,7.1.3.3.3,12.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877805,7.1.3.4.1,5.2,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877806,7.1.3.4.2,2.2,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877807,7.1.3.4.3,11.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877808,7.2.1.1.1,4.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877809,7.2.1.1.2,2.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877810,7.2.1.1.3,5.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877811,7.2.1.2.1,4.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877812,7.2.1.2.2,1.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877813,7.2.1.2.3,8.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877814,7.2.1.3.1,3.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877815,7.2.1.3.2,1.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877816,7.2.1.3.3,5.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877817,7.2.1.4.1,5.8,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877818,7.2.1.4.2,2.9,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877819,7.2.1.4.3,10.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877820,7.2.2.1.1,5.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877821,7.2.2.1.2,3.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877822,7.2.2.1.3,8.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877823,7.2.2.2.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877824,7.2.2.2.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877825,7.2.2.2.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877826,7.2.2.3.1,4.9,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877827,7.2.2.3.2,2.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877828,7.2.2.3.3,9.2,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877829,7.2.2.4.1,6.8,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877830,7.2.2.4.2,3.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877831,7.2.2.4.3,12.9,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877832,7.2.3.1.1,2.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877833,7.2.3.1.2,1.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877834,7.2.3.1.3,4.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877835,7.2.3.2.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877836,7.2.3.2.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877837,7.2.3.2.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877838,7.2.3.3.1,2.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877839,7.2.3.3.2,0.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877840,7.2.3.3.3,4.5,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877841,7.2.3.4.1,4.9,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877842,7.2.3.4.2,2.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877843,7.2.3.4.3,10.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877844,7.3.1.1.1,1.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877845,7.3.1.1.2,0.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877846,7.3.1.1.3,3.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877847,7.3.1.2.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877848,7.3.1.2.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877849,7.3.1.2.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877850,7.3.1.3.1,2.6,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877851,7.3.1.3.2,0.8,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877852,7.3.1.3.3,6.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877853,7.3.1.4.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877854,7.3.1.4.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877855,7.3.1.4.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877856,7.3.2.1.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877857,7.3.2.1.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877858,7.3.2.1.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877859,7.3.2.2.1,0.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877860,7.3.2.2.2,0.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877861,7.3.2.2.3,4.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877862,7.3.2.3.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877863,7.3.2.3.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877864,7.3.2.3.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877865,7.3.2.4.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877866,7.3.2.4.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877867,7.3.2.4.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877868,7.3.3.1.1,2.4,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877869,7.3.3.1.2,0.7,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877870,7.3.3.1.3,6.0,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877871,7.3.3.2.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877872,7.3.3.2.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877873,7.3.3.2.3,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877874,7.3.3.3.1,4.3,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877875,7.3.3.3.2,1.5,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877876,7.3.3.3.3,10.5,,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877877,7.3.3.4.1,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877878,7.3.3.4.2,,x,,,1
2021,Alberta,2016A000248,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877879,7.3.3.4.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877880,8.1.1.1.1,2.4,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877881,8.1.1.1.2,1.1,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877882,8.1.1.1.3,3.9,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877883,8.1.1.2.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877884,8.1.1.2.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877885,8.1.1.2.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877886,8.1.1.3.1,3.6,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877887,8.1.1.3.2,2.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877888,8.1.1.3.3,5.5,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877889,8.1.1.4.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877890,8.1.1.4.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877891,8.1.1.4.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877892,8.1.2.1.1,2.2,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877893,8.1.2.1.2,0.9,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877894,8.1.2.1.3,4.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877895,8.1.2.2.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877896,8.1.2.2.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877897,8.1.2.2.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877898,8.1.2.3.1,3.1,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877899,8.1.2.3.2,1.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877900,8.1.2.3.3,6.2,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877901,8.1.2.4.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877902,8.1.2.4.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877903,8.1.2.4.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877904,8.1.3.1.1,2.6,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877905,8.1.3.1.2,1.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877906,8.1.3.1.3,4.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877907,8.1.3.2.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877908,8.1.3.2.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877909,8.1.3.2.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877910,8.1.3.3.1,3.9,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877911,8.1.3.3.2,2.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877912,8.1.3.3.3,6.8,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877913,8.1.3.4.1,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877914,8.1.3.4.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877915,8.1.3.4.3,2.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877916,8.2.1.1.1,1.6,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877917,8.2.1.1.2,0.5,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877918,8.2.1.1.3,2.9,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877919,8.2.1.2.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877920,8.2.1.2.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877921,8.2.1.2.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877922,8.2.1.3.1,2.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877923,8.2.1.3.2,1.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877924,8.2.1.3.3,3.9,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877925,8.2.1.4.1,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877926,8.2.1.4.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877927,8.2.1.4.3,1.2,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877928,8.2.2.1.1,1.4,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877929,8.2.2.1.2,0.2,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877930,8.2.2.1.3,3.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877931,8.2.2.2.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877932,8.2.2.2.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877933,8.2.2.2.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877934,8.2.2.3.1,1.9,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877935,8.2.2.3.2,0.5,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877936,8.2.2.3.3,4.6,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877937,8.2.2.4.1,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877938,8.2.2.4.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877939,8.2.2.4.3,2.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877940,8.2.3.1.1,1.8,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877941,8.2.3.1.2,0.6,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877942,8.2.3.1.3,3.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877943,8.2.3.2.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877944,8.2.3.2.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877945,8.2.3.2.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877946,8.2.3.3.1,2.5,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877947,8.2.3.3.2,1.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877948,8.2.3.3.3,5.1,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877949,8.2.3.4.1,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877950,8.2.3.4.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877951,8.2.3.4.3,2.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877952,8.3.1.1.1,0.8,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877953,8.3.1.1.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877954,8.3.1.1.3,1.7,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877955,8.3.1.2.1,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877956,8.3.1.2.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877957,8.3.1.2.3,2.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877958,8.3.1.3.1,1.3,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877959,8.3.1.3.2,0.2,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877960,8.3.1.3.3,2.6,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877961,8.3.1.4.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877962,8.3.1.4.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877963,8.3.1.4.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277877964,8.3.2.1.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877965,8.3.2.1.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877966,8.3.2.1.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277877967,8.3.2.2.1,0.0,E,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877968,8.3.2.2.2,0.0,E,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877969,8.3.2.2.3,5.3,E,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277877970,8.3.2.3.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877971,8.3.2.3.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877972,8.3.2.3.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277877973,8.3.2.4.1,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877974,8.3.2.4.2,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877975,8.3.2.4.3,,x,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277877976,8.3.3.1.1,0.8,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877977,8.3.3.1.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877978,8.3.3.1.3,1.9,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277877979,8.3.3.2.1,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877980,8.3.3.2.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877981,8.3.3.2.3,4.1,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277877982,8.3.3.3.1,1.4,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877983,8.3.3.3.2,0.2,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877984,8.3.3.3.3,3.4,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277877985,8.3.3.4.1,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877986,8.3.3.4.2,0.0,,,,1
2021,British Columbia,2016A000259,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877987,8.3.3.4.3,2.3,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277877988,9.1.1.1.1,21.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877989,9.1.1.1.2,17.6,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877990,9.1.1.1.3,25.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277877991,9.1.1.2.1,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877992,9.1.1.2.2,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277877993,9.1.1.2.3,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277877994,9.1.1.3.1,20.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877995,9.1.1.3.2,14.6,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277877996,9.1.1.3.3,27.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277877997,9.1.1.4.1,38.9,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277877998,9.1.1.4.2,29.8,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277877999,9.1.1.4.3,49.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277878000,9.1.2.1.1,18.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878001,9.1.2.1.2,12.3,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878002,9.1.2.1.3,26.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277878003,9.1.2.2.1,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878004,9.1.2.2.2,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878005,9.1.2.2.3,9.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277878006,9.1.2.3.1,14.9,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878007,9.1.2.3.2,8.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878008,9.1.2.3.3,25.5,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277878009,9.1.2.4.1,44.1,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878010,9.1.2.4.2,30.5,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878011,9.1.2.4.3,59.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277878012,9.1.3.1.1,23.5,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878013,9.1.3.1.2,17.4,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878014,9.1.3.1.3,31.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277878015,9.1.3.2.1,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878016,9.1.3.2.2,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878017,9.1.3.2.3,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277878018,9.1.3.3.1,24.6,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878019,9.1.3.3.2,16.7,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878020,9.1.3.3.3,34.7,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277878021,9.1.3.4.1,33.7,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878022,9.1.3.4.2,22.3,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Overall,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878023,9.1.3.4.3,47.6,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277878024,9.2.1.1.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878025,9.2.1.1.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878026,9.2.1.1.3,0.8,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277878027,9.2.1.2.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878028,9.2.1.2.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878029,9.2.1.2.3,4.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277878030,9.2.1.3.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878031,9.2.1.3.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878032,9.2.1.3.3,1.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277878033,9.2.1.4.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878034,9.2.1.4.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878035,9.2.1.4.3,3.7,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277878036,9.2.2.1.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878037,9.2.2.1.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878038,9.2.2.1.3,1.7,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277878039,9.2.2.2.1,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878040,9.2.2.2.2,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878041,9.2.2.2.3,9.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277878042,9.2.2.3.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878043,9.2.2.3.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878044,9.2.2.3.3,2.7,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277878045,9.2.2.4.1,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878046,9.2.2.4.2,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878047,9.2.2.4.3,7.7,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277878048,9.2.3.1.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878049,9.2.3.1.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878050,9.2.3.1.3,1.4,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277878051,9.2.3.2.1,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878052,9.2.3.2.2,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878053,9.2.3.2.3,7.1,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277878054,9.2.3.3.1,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878055,9.2.3.3.2,0.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878056,9.2.3.3.3,2.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277878057,9.2.3.4.1,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878058,9.2.3.4.2,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Infection,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878059,9.2.3.4.3,7.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,Percent,Percent,239,units,0,v1277878060,9.3.1.1.1,21.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878061,9.3.1.1.2,17.6,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878062,9.3.1.1.3,25.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,Percent,Percent,239,units,0,v1277878063,9.3.1.2.1,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878064,9.3.1.2.2,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878065,9.3.1.2.3,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,Percent,Percent,239,units,0,v1277878066,9.3.1.3.1,20.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878067,9.3.1.3.2,14.6,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878068,9.3.1.3.3,27.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,Percent,Percent,239,units,0,v1277878069,9.3.1.4.1,38.9,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878070,9.3.1.4.2,29.8,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Both sexes,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878071,9.3.1.4.3,49.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,Percent,Percent,239,units,0,v1277878072,9.3.2.1.1,18.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878073,9.3.2.1.2,12.3,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878074,9.3.2.1.3,26.0,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,Percent,Percent,239,units,0,v1277878075,9.3.2.2.1,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878076,9.3.2.2.2,0.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878077,9.3.2.2.3,9.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,Percent,Percent,239,units,0,v1277878078,9.3.2.3.1,14.9,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878079,9.3.2.3.2,8.2,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878080,9.3.2.3.3,25.5,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,Percent,Percent,239,units,0,v1277878081,9.3.2.4.1,44.1,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878082,9.3.2.4.2,30.5,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Males,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878083,9.3.2.4.3,59.0,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,Percent,Percent,239,units,0,v1277878084,9.3.3.1.1,23.5,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878085,9.3.3.1.2,17.4,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 1 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878086,9.3.3.1.3,31.1,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,Percent,Percent,239,units,0,v1277878087,9.3.3.2.1,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878088,9.3.3.2.2,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 1 to 19,"High 95% confidence interval, percent",Percent,239,units,0,v1277878089,9.3.3.2.3,,x,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,Percent,Percent,239,units,0,v1277878090,9.3.3.3.1,24.6,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878091,9.3.3.3.2,16.7,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 20 to 59,"High 95% confidence interval, percent",Percent,239,units,0,v1277878092,9.3.3.3.3,34.7,,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,Percent,Percent,239,units,0,v1277878093,9.3.3.4.1,33.7,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"Low 95% confidence interval, percent",Percent,239,units,0,v1277878094,9.3.3.4.2,22.3,E,,,1
2021,Territories,2016A00016,Antibody seroprevalence - Vaccination,Females,Ages 60 and over,"High 95% confidence interval, percent",Percent,239,units,0,v1277878095,9.3.3.4.3,47.6,E,,,1
